Systemic bevacizumab appears to have significant promise and a low complication profile for the most treatment- resistant and aggressive forms of papillomatosis.
Adjuvant Therapies May Increase Time Between Surgeries for Recurrent Respiratory Papillomatosis
Recurrent respiratory papillomatosis is incurable with current treatment modalities, but adjuvant therapies should be used when surgery cannot control the disease.
Laryngeal Distribution of Recurrent Respiratory Papillomatosis
In untreated RRP patients presenting to three laryngology clinics, males had more anatomic sites affected by papilloma than females.
Prevalence of Dysplasia with Recurrent Respiratory Papillomatosis Is High
What is the prevalence of dysplasia in recurrent respiratory papillomatosis? Background: Recurrent respiratory papillomatosis (RRP) is a debilitating disease caused by the human papilloma virus (HPV). Between two percent and four percent of cases are reported to undergo malignant degeneration. Epithelial dysplasia is implicated in the progression towards malignancy. Study design: Retrospective case series review Setting: Two academic […]
Cidofovir Therapy Does Not Correlate with Worsening Dysplasia
What is the association between an increasing degree of papilloma dysplasia and the use of cidofovir in the context of the natural progression of dysplasia in recurrent respiratory papillomatosis (RRP)? Background: RRP is a benign disease characterized by recurrent lesions in the airway. The prevalence and degree of dysplasia present in the natural course of RRP […]